The purpose of this study is to evaluate the safety and tolerability of IPN01203, to determine the appropriate dose that can be given safely, and to assess whether the medication has any effect in fighting cancer. The study will also examine how the body processes the medication, how it affects the body, and whether the immune system develops antibodies against it. Additionally, researchers want to find out the best way to give this medication to people with these types of tumors.

The study is divided into different phases. In the first phase, different doses of IPN01203 will be tested to find the highest dose that can be given safely without causing serious side effects. In the next phase, the researchers will work to determine the best dosing schedule for the medication. Throughout the study, participants will be monitored for any side effects and their tumors will be measured using scans such as CT or MRI to see if the treatment is having any effect on the cancer. Blood tests and other assessments will be done regularly to check how the medication is working and how the body is responding to it.

The purpose of this study is to evaluate if continuing treatment after an initial period (called maintenance treatment) helps control cancer growth better than stopping treatment. The study is divided into two parts: an initial treatment period and a maintenance period. During the initial period, patients receive one of the study medications. Those who show stable disease or improvement may continue to the maintenance period.

The treatment plan involves taking medications either by mouth as tablets or through intravenous infusion (given directly into a vein). The medications are chosen based on specific features found in each patient’s tumor through molecular testing. The study monitors how well the treatment works and how long it can keep the cancer from growing, while also checking for any side effects that may occur during treatment.

The purpose of the study is to find the best dose of these medications when used together. Participants will receive both Sorafenib and Trametinib to see how their cancer responds to the treatment. The study will monitor how well the treatment works and any side effects that may occur. The trial will continue until the researchers determine the most effective and safe dose for future studies.

Participants in the study will have regular check-ups and tests, such as MRI or CT scans, to measure the size of their cancer and assess their overall health. The study aims to provide valuable information that could lead to better treatment options for people with cancers that have BRAF mutations.

During the trial, participants will receive TAK-280 and will be closely monitored by healthcare professionals. The study will also involve other medications like Tocilizumab and Siltuximab, which are also given through intravenous infusion. Some participants may receive a placebo instead of the active medication. The trial will help researchers learn more about how TAK-280 affects the body and how it might help in treating cancer.

Participants will visit the study site regularly for treatment and check-ups. These visits will allow the research team to monitor the participants’ health and any side effects they might experience. The study is expected to last for several months, and the information gathered will contribute to understanding the potential benefits and risks of TAK-280 for treating advanced cancer.

The purpose of the study is to evaluate how well these medications work when combined with stereotactic radiotherapy in treating vertebral metastases. Participants in the study will receive either Zoledronic Acid or Denosumab along with their radiation therapy. The study will last for up to 12 months, during which time the effects of the treatment will be monitored. This includes assessing the control of pain, the stability of the spine, and the prevention of bone complications. Participants will undergo regular check-ups, including imaging tests like MRI scans, to monitor the progress of their treatment.

The study aims to provide valuable information on the cost-effectiveness and overall benefits of adding these medications to standard radiation therapy for patients with vertebral metastases. By analyzing the outcomes, researchers hope to improve treatment strategies and enhance the quality of life for individuals affected by this condition.

The purpose of the study is to identify the best level of a specific molecule called ERBB2 mRNA that can predict how well patients will respond to Trastuzumab Deruxtecan in breast cancer. The study will involve collecting tumor samples from patients to analyze these levels and see how they relate to the overall response to the treatment. The study will also look at how these levels are associated with how long patients live without the cancer getting worse and their overall survival.

Throughout the study, researchers will also explore other factors, such as different types of breast cancer and immune-related genes, to see how they affect the response to Trastuzumab Deruxtecan. The study aims to develop a new way to predict who will benefit from this treatment and to understand any changes in the cancer that might lead to resistance to the treatment. The study is expected to continue until September 2027.

Participants in the study will receive either tislelizumab or spartalizumab through an intravenous infusion, which means the medication is given directly into a vein. The study will compare the effects of these medications on the tumors over a period of time. Some participants may receive a placebo, which is a substance with no active medication, to help researchers understand the true effects of the treatments. The study will monitor how the tumors respond, whether they shrink, remain stable, or grow, and will also track any side effects experienced by the participants.

The purpose of this study is to assess the overall response rate, which is the proportion of patients whose tumors show a complete or partial response to the treatment. Other aspects being evaluated include the duration of response, time to response, and overall survival of the participants. The study will also look at the clinical benefit rate, which includes patients whose disease remains stable for a certain period. This research is important for developing new treatment options for patients with advanced cancers that express high levels of the PD1 biomarker.

Participants in the study will either continue taking paracetamol or switch to a placebo while still receiving their regular opioid treatment. The study will observe how this change impacts their pain levels and any side effects related to opioid use. The trial will last for a short period, and participants will take the medications in tablet form.

The main goal is to see if stopping paracetamol leads to worse pain control compared to keeping it in the treatment plan. This information will help doctors understand the best way to manage pain for patients with metastatic cancer who are already using strong opioids.